Axogen, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Axogen Inc. (AXGN) completed its acquisition of BioCircuit Technologies, a medical device company. BioCircuit's NerveTape is FDA-cleared for nerve repair. Axogen expects BioCircuit to contribute $6M in Q4 2026 and $34M in 2027 revenue, excluding prior guidance. The company maintains its 2026 outlook for 24% revenue growth, 73% gross margin, and positive free cash flow.
Truist Securities reaffirmed a Buy rating on Axogen with a $53 price target, suggesting a 26.4% upside from the Sep 30 close. The firm cited Axogen's strong product portfolio and positive market feedback as key growth drivers.
Truist lowered AxoGen's price target to $53 from $60, citing dilution concerns but maintaining a Buy rating. The firm expects 20%+ annual revenue growth from 2026-2029. AxoGen reported Q2 2026 revenue of $69.7M, up 23% YoY, and a net loss of $1.5M. The company announced a $208.7M public offering. Analysts remain bullish, with a consensus Strong Buy rating.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning AXGN (Axogen, Inc.). Coverage has skewed bullish: 6 bullish, 0 neutral, and 2 bearish.
Recent AXGN coverage spans mergers & acquisitions, financial news and corporate actions.
In the last 30 days, AXGN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($174K). The most active reporter was TYNDALL JOSEPH A. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The deal adds a new product line and modest near‑term revenue, likely supporting the stock.
Analyst upgrade and higher price target suggest potential upside.
Dilution risk may weigh on the stock despite a still‑bullish target.
The acquisition is expected to be accretive to revenue growth and EPS, likely boosting Axogen's stock.
The large capital raise will increase share supply and may dilute existing shareholders, but provides funding for growth and M&A.
AlphAI scores every news story that mentions AXGN with an AI model for sentiment and relevance, and aggregates insider trades from Axogen, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Axogen Inc. (AXGN) completed its acquisition of BioCircuit Technologies, a medical device company. BioCircuit's NerveTape is FDA-cleared for nerve repair. Axogen expects BioCircuit to contribute $6M in Q4 2026 and $34M in 2027 revenue, excluding prior guidance. The company maintains its 2026 outlook for 24% revenue growth, 73% gross margin, and positive free cash flow.
1 min readTruist Securities reaffirmed a Buy rating on Axogen with a $53 price target, suggesting a 26.4% upside from the Sep 30 close. The firm cited Axogen's strong product portfolio and positive market feedback as key growth drivers.
1 min readTruist lowered AxoGen's price target to $53 from $60, citing dilution concerns but maintaining a Buy rating. The firm expects 20%+ annual revenue growth from 2026-2029. AxoGen reported Q2 2026 revenue of $69.7M, up 23% YoY, and a net loss of $1.5M. The company announced a $208.7M public offering. Analysts remain bullish, with a consensus Strong Buy rating.
2 min readAxogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for $200 million in cash, expected to close in Q4 2026. BioCircuit's NerveTape™ technology, which simplifies nerve repair, complements Axogen's portfolio. The deal is expected to boost revenue growth, adjusted EBITDA margin, and adjusted earnings per share post-closing, while maintaining positive free cash flow, according to Axogen.
2 min readAxogen (AXGN) raised $208.7m via a share offering at $42.50 each, alongside an M&A call. The company's stock is up 36% YTD and 157% over 1 year, but down 13% in the past month. Analysts estimate a fair value of $53.22, highlighting potential undervaluation and growth prospects, but also noting valuation risks and dependence on a single product.
2 min readAxogen (AXGN) stock fell 9.0% in pre-market trading after announcing a $200M acquisition of BioCircuit Technologies and a $208.7M equity raise at a 10% discount. The deal includes a 30-day over-allotment option. Axogen expects the acquisition to boost revenue, EBITDA, and earnings. The stock drop is attributed to the discounted equity offering.
2 min readAxogen (AXGN) agreed to acquire BioCircuit Technologies for $200M, adding NerveTape, an FDA-approved sutureless nerve repair device. The deal is expected to boost revenue, EBITDA, and EPS while maintaining positive cash flow. Axogen plans to fund the acquisition with proceeds from a common stock offering. The transaction is set to close in Q4 2026, subject to conditions.
2 min readAxogen, Inc. (AXGN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies Acquisition adds NerveTape™, the 1st FDA-approved device for sutureless peripheral nerve repair, broadening Axogen’s addressable market within its focus markets Axogen’s commercial infrastruct
2 min readWall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include argenx (ARGX) to Buy at UBS, DT Midstream (DTM) to Outperform at Wolfe Research, and SolarEdge (SEDG) to Buy at UBS. Downgrades include Dick's Sporting Goods (DKS) to Hold at Truist, EPAM Systems (EPAM) to Neutral at JPMorgan, and Intuit (INTU) to Neutral at Bank of America. Initiations include Atlassian (TEAM) with Outperform at RBC, JFrog (FROG) with Outperform at RBC, and Lattice Semicond
4 min readBegan Marc A (EVP & General Counsel) sold 67,500 shares of Axogen, Inc. (AXGN) at $47.34 ($3.20M total) on 2026-08-10 under a Rule 10b5-1 trading plan.
1 min read
